Research progress on the mechanism of serum amyloid A in ophthalmic diseases

doi:10.3877/cma.j.issn.2095-2007.2022.02.011

Abstract

Abstract:

Serum amyloid A (SAA) is a nonspecific acute reactive protein. There is usually a very low level in the blood of healthy people. During the period of acute inflammation for patients, the plasma concentration of SAA could increase by more than 1000 times. The increase of SAA levels is resulted from the physical damage for cells, including infection, trauma, inflammation and cancer. When the body occurs a small area of inflammation stimulation, the SAA level will be significantly higher than the normal range. Therefore, SAA has become the most sensitive marker reflecting inflammatory infection at present. SAA combined with detection of blood routine examination and C-reactive protein had been widely used in systemic inflammatory diseases in the recent years, which could provide a strong diagnostic basis for the differential diagnosis of bacterial and viral infection in the early stage. However, the advances on the clinical application of SAA in local inflammatory diseases is rarely reported. Thus, the clinical application of SAA in ophthalmology were reviewed.

Key words: Serum amyloid A, Ophthalmic diseases, Infectious keratitis

Xiaona Liu, Wei Wang, Feng Wu, Tao Song, Meiqin Zheng, Laibao Zheng. Research progress on the mechanism of serum amyloid A in ophthalmic diseases[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(02): 120-124.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2022.02.011

https://zhykyxzz.cma-cmc.com.cn/EN/Y2022/V12/I02/120

References 60

[1]	Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states[J]. Curr Opin Hematol, 2000, 7(1): 64-69.
[2]	Upragarin N, Asten AJ, Tooten PC, et al. Serum amyloid A production by chicken fibroblast-like synoviocytes[J]. Vet Immunol Immunopathol, 2005, 106(1-2): 39-51.
[3]	Soriĉ Hosman I, Kos I, Lamot L. Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker[J]. Front Immunol, 2020, 11: 631299.
[4]	Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation[J]. J Leukoc Biol, 2015, 98(6): 923-929.
[5]	De Buck M, Gouwy M, Wang JM, et al. Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults[J]. Curr Med Chem, 2016, 23(17): 1725-1755.
[6]	de Seny D, Cobraiville G, Charlier E, et al. Acute-phase serum amyloid a in osteoarthritis: regulatory mechanism and proinflammatory properties[J]. PLoS One, 2013, 8(6): e66769.
[7]	Ma M, Defranoux N, Li W, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis[J]. Arthritis Res Ther, 2020, 22(1): 158.
[8]	Kutulculer N, Karaca NE, Azarsiz E, et al. Immunoglobulin light chain levels can be used to determine disease stage in children with juvenile idiopathic arthritis[J]. Clin Lab Sci, 2011, 24(2): 93-98.
[9]	Cantarini L, Giani T, Fioravanti A, et al. Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis[J]. Yonsei Med J, 2012, 53(5): 1045-1048.
[10]	Dev S, Singh A. Study of role of serum amyloid A (SAA) as a marker of disease activity in juvenile idiopathic arthritis[J]. J Family Med Prim Care, 2019, 8(6): 2129-2133.
[11]	Miyamae T, Malehorn DE, Lemster B, et al. Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy[J]. Arthritis Res Ther, 2005, 7(4): R746-R755.
[12]	Li X, Wang L, Yan S, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China[J]. Int J Infect Dis, 2020，94：128-132.
[13]	Mo XN, Su ZQ, Lei CL, et al. Serum amyloid A is a predictor for prognosis of COVID-19[J]. Respirology, 2020, 25(7): 764-765.
[14]	Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis[J]. Arthritis Rheum, 2009, 61(11): 1580-1585.
[15]	Cocco E, Bellone S, El-Sahwi K, et al. Serum amyloid A: a novel biomarker for endometrial cancer[J]. Cancer, 2010, 116(4): 843-851.
[16]	Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, et al. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis[J]. J Histochem Cytochem, 2010, 58(11): 1015-1023.
[17]	Sung HJ, Ahn JM, Yoon YH, et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer[J]. J Proteome Res, 2011, 10(3): 1383-1395.
[18]	Wang JY, Zheng YZ, Yang J, et al. Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma[J]. BMC Cancer, 2012, 12: 365.
[19]	Shen C, Sun XG, Liu N, et al. Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis[J]. Mol Med Rep, 2015, 11(2): 1528-1534.
[20]	Ren SW, Qi X, Jia CK, et al. Serum amyloid A and pairing formyl peptide receptor 2 are expressed in corneas and involved in inflammation-mediated neovascularization[J]. Int J Ophthalmol, 2014, 7(2): 187-193.
[21]	Ma Y, Tao Y, Lu Q, et al. Intraocular expression of serum amyloid a and interleukin-6 in proliferative diabetic retinopathy[J]. Am J Ophthalmol, 2011, 152(4): 678-685.
[22]	Baltmr A, Lightman S, Tomkins-Netzer O. Vogt-Koyanagi-Harada syndrome-current perspectives[J]. Clin Ophthalmol, 2016, 10: 2345-2361.
[23]	Mizuno M, Fujinami K, Watanabe K, et al. Macular Hole Associated with Vogt-Koyanagi-Harada Disease at the Acute Uveitic Stage[J]. Case Rep Ophthalmol, 2015, 6(3): 328-332.
[24]	Sheu SJ. Update on uveomeningoencephalitides[J]. Curr Opin Neurol, 2005, 18(3): 323-329.
[25]	Yamaki K, Gocho K, Sakuragi S. Pathogenesis of Vogt-Koyanagi-Harada disease[J]. Int Ophthalmol Clin, 2002, 42(1): 13-23.
[26]	Li K, Yang P, Zhao M, et al. Polymorphisms of FCRL3 in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome[J]. Mol Vis, 2009, 15: 955-961.
[27]	Ghazala A, Keefe GA, Rao NA. Vogt-Koyanagi-Harada disease[J]. Surv Ophthalmol, 2017, 62(1) ：1-25.
[28]	Yang P, Ye Z, Xu J, et al. Macular Abnormalities in Vogt-Koyanagi-Harada Disease[J]. Ocul Immunol Inflamm, 2019, 27(8): 1195-1202.
[29]	Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment[J]. Prog Retin Eye Res, 2016, 52: 84-111.
[30]	杨媛媛，李亚利，王大选，等. 血清淀粉样蛋白A在Vogt-小柳原田综合征早期临床诊断中的价值[J]. 温州医科大学学报，2019，49(7)：512-516.
[31]	Lopalco G, Lucherini OM, Vitale A, et al. Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet′s Disease[J]. Medicine (Baltimore), 2015, 94(42): e1858.
[32]	Vitale A, Rigante D, Lopalco G, et al. Serum amyloid-A in Behcet′s disease[J]. Clin Rheumatol, 2014, 33(8): 1165-1167.
[33]	Vitale A, Sota J, Rigante D, et al. Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools and Therapeutic Perspectives[J]. Curr Rheumatol Rep, 2016, 18(1): 3.
[34]	周桢源，林艳伟，沈南，等. 血清急性淀粉样蛋白A水平与白塞病活动度的相关性研究[J]. 上海交通大学学报(医学版)，2017，37(7)：955-958.
[35]	Lee MS, Yoo SA, Cho CS, et al. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis[J]. J Immunol, 2006, 177(8): 5585-5594.
[36]	Jenkins AJ, Joglekar MV, Hardikar AA, et al. Biomarkers in Diabetic Retinopathy[J]. Rev Diabet Stud, 2015, 12(1-2): 159-195.
[37]	王淑娜，张玉芝，伊正君，等. 血清淀粉样蛋白A与2型糖尿病性视网膜病变相关性分析[J]. 潍坊医学院学报，2019，41(2)：136-138.
[38]	Robinson PC, Leo PJ, Pointon JJ, et al. The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis[J]. Genes Immun, 2016, 17(1): 46-51.
[39]	Robinson PC, Claushuis TA, Cortes A, et al. Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis[J]. Arthritis Rheumatol, 2015, 67(1): 140-151.
[40]	Dai ML, Fan S, Li Z, et al. Correlation of serum amyloid A levels, clinical manifestations, treatment, and disease activity in patients with acute anterior uveitis[J]. Eye (Lond), 2020, 34(9): 1672-1678.
[41]	Mitulescu TC, Stavaru C, Voinea LM, et al. The role of Vitamin D in immuno-inflammatory responses in Ankylosing Spondylitis patients with and without Acute Anterior Uveitis[J]. J Med Life, 2016, 9(1): 26-33.
[42]	冯振华，王大博，韩静，等. 葡萄膜炎患者血清淀粉样蛋白A的测定及临床意义[J]. 眼科新进展，2010，30(2)：164-166.
[43]	Durand ML. Bacterial and Fungal Endophthalmitis[J]. Clin Microbiol Rev, 2017, 30(3): 597-613.
[44]	Miller FC, Coburn PS, Huzzatul MM, et al. Targets of immunomodulation in bacterial endophthalmitis[J]. Prog Retin Eye Res, 2019, 73: 100763.
[45]	杨媛媛，李亚利，陈鹏飞，等. 血清淀粉样蛋白A检测对感染性眼内炎诊断的临床价值[J]. 国际眼科杂志，2019，19(10)：1738-1740.
[46]	Keay L, Stapleton F, Schein O. Epidemiology of contact lens-related inflammation and microbial keratitis: a 20-year perspective[J]. Eye Contact Lens, 2007, 33(6): 346-353.
[47]	Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis[J]. Cornea, 2008, 27(1): 22-27.
[48]	Saha S, Banerjee D, Khetan A, et al. Epidemiological profile of fungal keratitis in urban population of West Bengal, India[J]. Oman J Ophthalmol, 2009, 2(3): 114-118.
[49]	Sheng XL, Li HP, Liu QX, et al. Prevalence and associated factors of corneal blindness in Ningxia in northwest China[J]. Int J Ophthalmol, 2014, 7(3): 557-562.
[50]	Gupta N, Tandon R, Gupta SK, et al. Burden of corneal blindness in India[J]. Indian J Community Med, 2013, 38(4): 198-206.
[51]	Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective[J]. Bull World Health Organ, 2001, 79(3): 214-221.
[52]	Wong T, Ormonde S, Gamble G, et al. Severe infective keratitis leading to hospital admission in New Zealand[J]. Br J Ophthalmol, 2003, 87(9): 1103-1108.
[53]	Kampitak K, Suntisetsin H, Sirikul T. Clinical and microbiological characteristics of corneal ulcers in a Thai referral center[J]. Brief communication (Original), 2014, 8(2)：275-282.
[54]	Mandour SS, Marey HM, Farahat HG. Resistant Microbial Keratitis in South Nile Delta, Egypt: Influence of Regional Risk Factors[J]. Semin Ophthalmol, 2016, 31(5): 473-478.
[55]	Whitcher JP, Srinivasan M. Corneal ulceration in the developing world--a silent epidemic[J]. Br J Ophthalmol, 1997, 81(8): 622-623.
[56]	Sridhar MS, Gopinathan U, Garg P, et al. Aspergillus fumigatus keratitis with wreath pattern infiltrates[J]. Cornea, 2001, 20(5): 534-535.
[57]	El-Aal AM, El Sayed M, Mohammed E, et al. Evaluation of herpes simplex detection in corneal scrapings by three molecular methods[J]. Curr Microbiol, 2006, 52(5): 379-382.
[58]	Cao J, Yang Y, Yang W, et al. Prevalence of infectious keratitis in Central China[J]. BMC Ophthalmol, 2014, 14: 43.
[59]	Moshirfar M, Hopping GC, Vaidyanathan U, et al. Biological Staining and Culturing in Infectious Keratitis: Controversy in Clinical Utility[J]. Med Hypothesis Discov Innov Ophthalmol, 2019, 8(3): 145-151.
[60]	中国中西医结合学会检验医学专业委员会. 血清淀粉样蛋白A在感染性疾病中临床应用的专家共识[J]. 中华检验医学杂志，2019，42(3)：186-192.

Please choose a citation manager

Content to export